BSE Live
Dec 05, 16:01Prev. Close
1974.15
Open Price
1966.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 05, 15:59Prev. Close
1973.80
Open Price
1964.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1968.20 (678)
| Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,231.55 | 501.92 | 379.95 | 284.10 | 250.79 | |
| Net CashFlow From Operating Activities | 145.11 | 114.24 | 284.96 | 194.65 | 421.06 | |
| Net Cash Used In Investing Activities | -394.50 | 216.55 | -151.24 | 601.53 | -654.72 | |
| Net Cash Used From Financing Activities | -32.39 | -384.66 | -13.77 | -779.73 | 259.40 | |
| Foreign Exchange Gains / Losses | -0.42 | -5.80 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 218.46 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -63.74 | -59.68 | 119.95 | 16.46 | 25.74 | |
| Cash And Cash Equivalents Begin of Year | 105.76 | 165.44 | 45.49 | 29.03 | 3.29 | |
| Cash And Cash Equivalents End Of Year | 42.02 | 105.76 | 165.44 | 45.49 | 29.03 |
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
18.11.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015